Tyrosine kinase fusion genes and potential targeted therapies in myeloid/lymphoid neoplasms with eosinophilia
| Tyrosine kinase gene . | Most common partner fusion gene . | Other partner fusion genes and chromosome breakpoint . | Tyrosine kinase inhibitors with established or potential activity . | |
|---|---|---|---|---|
| PDGFRA (4q12) | FIP1L1 (4q12) | BCR (22q11) KIF5B (10p11) TNKS2 (10q23) CDK5RAP2 (9q33) | ETV6 (12p13) STRN (2p24) FOXP1 (3p14) | Imatinib |
| PDGFRB (5q31 ~ 33) | ETV6 (12p13) | SPTBN1 (2p16) PDE4DIP (1q22) WDR48 (3p22) GOLGB1 (3q12) DIAPH1 (5q31) KANK1 (9p24) CEP85L (6q22) GIT2 (12q24) HIP1 (7q11) NIN (14q24) ERC1 (12p13) DTD1 (20p11) MYO18A (17q11) NDE1 (16p13). CPSF6 (12q15) CCDC88C (14q32) | TPM3 (1q21) SPDR (2q32) GOLGA4 (3p22) PRKG2 (4q21) TNIP1 ((5q33) SART3 ((12q23) CCDC6 (10q21) NDEL1 (17p13) GPIAP1 (11p13) SPECC1 (17p11) TRIP11 (14q32) RABEP1 (17p13) MPRIP (17p11) TP53BP1 (15q22) BIN2 (12q13) | Imatinib |
| FGFR1 (8p11) | ZMYM2 (13q12) | FGFR1OP (6q27) LRRFIP1 (2q37) SQSTM1 (5q35) TRIM24 (7q34) HERV-K (19q13) BCR (22q11) CPSF6 (12q15) | CNTRL (9q33) RANBP2 (2q13) CUX1 (7q22) TPR1 (1q25) FGFR1OP2 (12p11) MYO18A (17q11) TFG (3q12) | Pemigatinib Futibatinib Midostaurin Ponatinib |
| JAK2 (9p24) | PCM1 (8p21) | ETV6 (12p13) BCR (22q11) | Ruxolitinib Fedratinib Pacritinib Momelotinib | |
| FLT3 (13q12) | ETV6 (12p13) | SPTBN1 (2p16) TRIP11 (14q32) LYN (8q12) | GOLGB1 (3q12) NTRK3 (15q25) SYK (9q22) | Gilteritinib Midostaurin Sorafenib Sunitinib |
| ABL1 (9q34) | ETV6 (12p13) | Dasatinib Nilotinib Imatinib Bosutinib Ponatinib Asciminib |
| Tyrosine kinase gene . | Most common partner fusion gene . | Other partner fusion genes and chromosome breakpoint . | Tyrosine kinase inhibitors with established or potential activity . | |
|---|---|---|---|---|
| PDGFRA (4q12) | FIP1L1 (4q12) | BCR (22q11) KIF5B (10p11) TNKS2 (10q23) CDK5RAP2 (9q33) | ETV6 (12p13) STRN (2p24) FOXP1 (3p14) | Imatinib |
| PDGFRB (5q31 ~ 33) | ETV6 (12p13) | SPTBN1 (2p16) PDE4DIP (1q22) WDR48 (3p22) GOLGB1 (3q12) DIAPH1 (5q31) KANK1 (9p24) CEP85L (6q22) GIT2 (12q24) HIP1 (7q11) NIN (14q24) ERC1 (12p13) DTD1 (20p11) MYO18A (17q11) NDE1 (16p13). CPSF6 (12q15) CCDC88C (14q32) | TPM3 (1q21) SPDR (2q32) GOLGA4 (3p22) PRKG2 (4q21) TNIP1 ((5q33) SART3 ((12q23) CCDC6 (10q21) NDEL1 (17p13) GPIAP1 (11p13) SPECC1 (17p11) TRIP11 (14q32) RABEP1 (17p13) MPRIP (17p11) TP53BP1 (15q22) BIN2 (12q13) | Imatinib |
| FGFR1 (8p11) | ZMYM2 (13q12) | FGFR1OP (6q27) LRRFIP1 (2q37) SQSTM1 (5q35) TRIM24 (7q34) HERV-K (19q13) BCR (22q11) CPSF6 (12q15) | CNTRL (9q33) RANBP2 (2q13) CUX1 (7q22) TPR1 (1q25) FGFR1OP2 (12p11) MYO18A (17q11) TFG (3q12) | Pemigatinib Futibatinib Midostaurin Ponatinib |
| JAK2 (9p24) | PCM1 (8p21) | ETV6 (12p13) BCR (22q11) | Ruxolitinib Fedratinib Pacritinib Momelotinib | |
| FLT3 (13q12) | ETV6 (12p13) | SPTBN1 (2p16) TRIP11 (14q32) LYN (8q12) | GOLGB1 (3q12) NTRK3 (15q25) SYK (9q22) | Gilteritinib Midostaurin Sorafenib Sunitinib |
| ABL1 (9q34) | ETV6 (12p13) | Dasatinib Nilotinib Imatinib Bosutinib Ponatinib Asciminib |